CYP2C19 (+ or -)*2/(+ or -)*17 Diplotypes: Prognostic impactson patients with acute coronary syndrome


Purpose: To investigate the prognostic impacts of a combined clopidogrel-metabolizing genotypes CYP 2C19 (+ or -)*2/(+ or -)*17 on patients with acute coronary syndrome (ACS). Population and methods: Prospective, longitudinal study of 95 patients admitted for ACS to a single coronary care unit. Patients less than 75 years of age, who survived hospitalization and to whom clopidogrel was prescribed, were included. CYP2C19 genotyping was performed at dis- charge. For analysis, the patients were grouped as follows: Group A ([+]*2/[+]*17) n = 8; Group B ([+]*2/[-]*17) n = 18; Group C ([-]*2/[+]*17) n = 27; and Group D ([-]*2/[-]*17) n = 42. Platelet function was assessed by an ADP platelet aggregation test using a commercially available kit. The primary end-point was a composite of mortality or readmission for ACS. The median time of follow-up was 136.0 (79.0 - 188.0) days. Results: The mean age of the study patients was 59.9 ± 10.7 years, and 83.2% were male. The allele frequencies of CYP2C19*2 and CYP2C19 *17 were 14.2% and 20%, respectively. Both allele frequencies were in Hardy Weinberg equilibrium. The patient groups were homogenous for demographic data, cardiovascular risk factors, GRACE and CRUSADE bleeding scores, left ventricular ejection fraction, and coronary anatomy. ADP platelet aggre-gation was similar for all groups (respective rates for groups A, B, C, D were 17.5 U (10.3 – 18.7) vs 20.0 U (17.3 – 26.8) vs 16 U (12 – 19) vs 12 U (8 – 22), p = 0.4). Event-free survival was significantly lower for group B (respective rates for Groups A, B, C, D were 87.5% vs 68.8% vs 96.3% vs 92.5%; p = 0.02). By multivariate Cox regression analysis, the CYP2C19 (+)*2/(-)*17 diplotype was an independent predictor of outcome, conferring a 5.2-fold higher adjusted risk for the composite endpoint than the others diplotypes. Conclusion: In our study, patients with the intermediate plus non-ultrarapid clopidogrel-metabolizing genotype ([+]*2/[-]*17) had a significantly poor medium-term prognosis for ischemic events, compared with the other diplotypes.

Share and Cite:

Teixeira, R. , Grazina, M. , Monteiro, P. , Soares, F. , Lourenço, M. and Pêgo, G. (2012) CYP2C19 (+ or -)*2/(+ or -)*17 Diplotypes: Prognostic impactson patients with acute coronary syndrome. World Journal of Cardiovascular Diseases, 2, 260-268. doi: 10.4236/wjcd.2012.24041.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Savi, P., Pereillo, J.M., Uzabiaga, M.F., Combalbert, J., Picard, C., Maffrand, J.P., et al. (2000) Identification and biological activity of the active metabolite of clopidogrel. Journal of Thrombosis and Haemostasis, 84, 891-896.
[2] Hulot, J.S., Bura, A., Villard, E., Azizi, M., Remones, V., Goyenvalle, C., et al. (2006) Cytochrome P450 2C19 loss- of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 108, 2244-2247. doi:10.1182/blood-2006-04-013052
[3] Sibbing, D., Gebhard, D., Koch, W., Braun, S., Stegherr, J., Morath, T., et al. (2010) Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. Journal of Thrombosis and Haemostasis, 8, 1685-1693. doi:10.1111/j.1538-7836.2010.03921.x
[4] Chan, M.Y., Tan, K., Tan, H.C., Huan, P.T., Li, B., Phua, Q.H., et al. (2012) CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics, 13, 533-542. doi:10.2217/pgs.12.24
[5] Geisler, T., Schaeffeler, E., Dippon, J., Winter, S., Buse, V., Bischofs, C., et al. (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics, 9, 1251-1259. doi:10.2217/14622416.9.9.1251
[6] Hochholzer, W., Trenk, D., Bestehorn, H.P., Fischer, B., Valina, C.M., Ferenc, M., et al. (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. Journal of the American College of Cardiology, 48, 1742-1750. doi:10.1016/j.jacc.2006.06.065
[7] Sibbing, D., Stegherr, J., Latz, W., Koch, W., Mehilli, J., Dorrler, K., et al. (2009)Cytochrome P450 2C19 loss-of- function polymorphism and stent thrombosis following percutaneous coronary intervention. European Heart Journal, 30, 916-922. doi:10.1093/eurheartj/ehp041
[8] Collet, J.P., Hulot, J.S., Pena, A., Villard, E., Esteve, J.B., Silvain, J., et al. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet, 373, 309- 317. doi:10.1016/S0140-6736(08)61845-0
[9] Shuldiner, A.R., O’Connell, J.R., Bliden, K.P., Gandhi, A., Ryan, K., Horenstein, R.B., et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 302, 849-857. doi:10.1001/jama.2009.1232
[10] Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Hockett, R.D., Brandt, J.T., et al. (2009)Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine, 360, 354-362. doi:10.1056/NEJMoa0809171
[11] Zabalza, M., Subirana, I., Sala, J., Lluis-Ganella, C., Lucas, G., Tomas, M., et al. (2012) Meta-analyses of the association between cytochrome CYP2C19 loss- and gain- of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart, 98, 100-108. doi:10.1136/hrt.2011.227652
[12] Mega, J.L., Simon, T., Collet, J.P., Anderson, J.L., Antman, E.M., Bliden, K., et al. (2010)Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA, 304, 1821-1830. doi:10.1001/jama.2010.1543
[13] Sim, S.C., Risinger, C., Dahl, M.L., Aklillu, E., Christensen, M., Bertilsson, L., et al. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clinical Pharmacology & Therapeutics, 79, 103-113. doi:10.1016/j.clpt.2005.10.002
[14] Sibbing, D., Koch, W., Gebhard, D., Schuster, T., Braun, S., Stegherr, J., et al. (2010) Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation, 121, 512-518. doi:10.1161/CIRCULATIONAHA.109.885194
[15] Tiroch, K.A., Sibbing, D., Koch, W., Roosen-Runge, T., Mehilli, J., Schomig, A., et al. (2010) Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. American Heart Journal, 160, 506-512. doi:10.1016/j.ahj.2010.06.039
[16] The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: Study design and rationale. American Heart Journal. 2009, 158, 327-344.
[17] Chin, C.T., Roe, M.T., Fox, K.A., Prabhakaran, D., Marshall, D.A., Petitjean, H., et al. (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non- ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syn-dromes (TRI- LOGY ACS) trial. American Heart Journal, 160, 16-22.
[18] Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.S., Johnson, J.A., et al. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clinical Pharmacology & Therapeutics, 90, 328-332. doi:10.1038/clpt.2011.132
[19] Thygesen, K., Alpert, J.S. and White, H.D. (2007) Universal definition of myocardial infarction. European Heart Journal, 28, 2525-2538.
[20] Anderson, J.L., Adams, C.D., Antman, E.M., Bridges, C.R., Califf, R.M., Casey Jr., D.E., et al. (2007) ACC/ AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction): Developed in collaboration with the Americ
[21] Gurbel, P.A., Tantry, U.S., Shuldiner, A.R. and Kereiakes, D.J. (2010) Genotyping: One piece of the puzzle to personalize antiplatelet therapy. Journal of the American College of Cardiology, 56, 112-116. doi:10.1016/j.jacc.2010.04.008
[22] Gurbel, P.A., Tantry, U.S. and Shuldiner, A.R. (2010) Letter by Gurbel et al. regarding article, “Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement”. Circulation, 122, 478. doi:10.1161/CIRCULATIONAHA.110.943548
[23] Harmsze, A.M., van Werkum, J.W., Hackeng, C.M., Ruven, H.J., Kelder, J.C., Bouman, H.J., et al. (2012) The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22, 169-175. doi:10.1097/FPC.0b013e32834ff6e3
[24] Santos, P.C., Soares, R.A., Santos, D.B., Nascimento, R.M., Coelho, G.L., Nicolau, J.C., et al. (2011) CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Medical Genetics, 12, 13. doi:10.1186/1471-2350-12-13

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.